73 / 90
QUESTIONS A
FRANÇOIS LIOTARD
DIRECTEUR GÉNÉRAL
DE LISI AUTOMOTIVE
“On average, our sites have
launched 15%of new references
compared to the previous year.”
What were the highlights of 2018?
Firstly, we successfully commissioned the
capacity investments initiated in 2016-2017 at
our Big Lake andCoonRapids sites in theUnited
States, wherewe launched newmachining
processes, aswell as at our Hérouville-Saint-Clair
in France unit
(see also p. 45). Themanagement
teamhas also been renewed - a newChief
ExecutiveOfficer and an Industrial Manager were
appointed in 2018 - combining international
experience in the field of health industries and
strong industrial expertise.
Finally, we have set up a production unit dedicated
to the prototyping of orthopedic implants
and instruments at our Neyron site in France.
We are now therefore in a position to offer our
customers preserial production runs bymobilizing
productionmeans identical or comparable
to those used for large series. This reduces
significantly the approval steps required to
launch their newproducts.
What are the prospects for 2019?
The healthmarket is characterized by the
constant search for innovation. The systemset up
at Neyron enabled us to contribute to the launch
of newproducts as early as 2018. On average,
our sites have launched 15%of new references
compared to the previous year. For some of them,
this proportion has reachedmore than 50%.
We are therefore ideally positioned to respond as
soon as our customers launch their newproduct
lines. For us, thismeans therewill be future
volumes to produce. This has been particularly
true for example in the segment of surgical
robotics, thanks to the relationshipwe havewith
themain players in thismarket. LISI MEDICAL
is thus ideally positioned to assist its customers
in the deployment of high value-added robotic
systems in hospitals. This revolution enhances
the precision of procedures and limits
post-operative incidents.
QUESTIONS TO
JEAN-M RC DURANO
CHIEF EXECUTIVE OFFICER
LISI MEDICAL
3
69